Residual Solvent Testing Explained: Headspace GC and the ICH Q3C Classes

Published November 2026 · Patriot Labs Research Team · ~20 min read

The short answer

Residual solvent testing measures the volatile organic solvent left behind in a drug substance, excipient or synthetic peptide after it is made and dried. The standard method is static headspace gas chromatography, which separates and quantifies each solvent, and the result is judged against the limits in the ICH Q3C guideline and pharmacopoeial chapters such as USP General Chapter <467>. It is a test for one specific class of impurity — leftover process solvents — not a measure of chemical purity, identity or potency.

The reason the test exists is that solvents are unavoidable and, in some cases, dangerous. A peptide is assembled on a resin suspended in dimethylformamide, cleaved with trifluoroacetic acid, crashed out of solution with cold ether and polished in a water–acetonitrile gradient; a small-molecule drug passes through its own list. ICH Q3C defines residual solvents as “organic volatile chemicals that are used or produced in the manufacture of drug substances or excipients, or in the preparation of drug products,” and notes that they “are not completely removed by practical manufacturing techniques.”^[1][2] Because they carry no therapeutic benefit and some are toxic, the guideline’s governing principle is that “all residual solvents should be removed to the extent possible.”^[1]

What a laboratory does, then, is identify which solvents the process could have left, measure them, and compare each against its limit. The measurement is almost always made by heating the sample in a sealed vial so the solvents evaporate into the headspace, sampling that gas, and separating it on a gas chromatograph. The rest of this guide works through the chemistry of residual solvents, the three-class framework that sets their limits, the mechanics of the headspace method, and what a residual-solvent value on a research certificate of analysis can and cannot tell you.

What a residual solvent actually is

A residual solvent is a trace of a liquid that was used to carry out a chemical reaction or a purification, and that remained trapped in the solid product when the liquid was removed. Understanding the test starts with seeing that this is a different kind of impurity from the ones a purity assay is built to find.

The impurities covered in Peptide Impurities Explained — deletion sequences, truncated chains, oxidised or deamidated residues — are molecules closely related to the target peptide, and they show up as extra peaks in the same HPLC run that measures purity. A residual solvent is not related to the peptide at all. It is a small, volatile organic molecule — dimethylformamide, acetonitrile, methanol — physically held in the powder, often hydrogen-bonded to the peptide or occluded in the solid during lyophilization. Because it is small and volatile, it tends to be invisible to the reversed-phase HPLC gradient used for purity, which is tuned to separate peptides, not to detect the solvent front. It needs a method of its own.

That distinction matters for how the number is read. A purity figure of, say, 99 percent by HPLC describes how much of the peptide-related material is the intended sequence; it says nothing about how much solvent is sitting alongside the peptide. The two are measured separately and reported separately, which is why a complete research report can carry an HPLC purity line, a mass-spectrometry identity line, a water-content line, and a residual-solvent line, each answering a different question.

Why residual solvents are controlled

Residual solvents are controlled because some of them are genuinely hazardous and because, unlike the active substance, they do nothing useful once the product is made. ICH Q3C puts it plainly: “Since there is no therapeutic benefit from residual solvents, all residual solvents should be removed to the extent possible to meet product specifications, good manufacturing practices, or other quality-based requirements.”^[1]

The hazard is not uniform. A few solvents are known or strongly suspected human carcinogens — benzene is the classic example — or serious environmental toxicants, and the guideline’s position on these is that they should not be used at all unless their use is unavoidable, in which case they are held to extremely low limits.^[1][2] A larger group causes lower-grade but still real toxicity: animal carcinogenicity, neurotoxicity, teratogenicity or reversible organ effects. A third group is of low toxic potential and is controlled mainly as a matter of good manufacturing practice rather than health risk. The framework that sorts solvents into these groups, and attaches a number to each, is the subject of the next section.

For a research material the logic is the same, read in a laboratory key. A solvent residue is a confounder: it can interfere with an assay, alter how a compound behaves in a cell-culture system, or simply indicate that a batch was not dried or purified as thoroughly as it should have been. Residual-solvent data is therefore one of the quality signals a careful buyer looks for, alongside purity, identity and water content.

The three ICH Q3C classes

ICH Q3C sorts solvents into three classes according to the risk they pose to health, and the class decides how tightly a solvent is limited. The guideline is maintained by the International Council for Harmonisation and is implemented almost verbatim by the regional pharmacopoeias; its current version is Q3C(R9), adopted at ICH Step 4 on 24 January 2024 and brought into effect in Europe on 29 April 2024, with the R9 change being a minor revision on how solvent volatility is considered in method validation.^[1][2]

Class 1 — solvents to be avoided. These are “known human carcinogens, strongly suspected human carcinogens, and environmental hazards.”^[1] They are not to be used in manufacture unless unavoidable, and they carry the lowest limits in the guideline, expressed directly in parts per million. The full list is short.

Class 2 — solvents to be limited. These are “non-genotoxic animal carcinogens or possible causative agents of other irreversible toxicity such as neurotoxicity or teratogenicity,” along with solvents suspected of other significant but reversible toxicities.^[1] Each is assigned a permitted daily exposure in milligrams per day and a corresponding concentration limit in ppm. This is the class that matters most for peptides, because the common synthesis and purification solvents live here.

Class 3 — solvents of low toxic potential. These “may be regarded as less toxic and of lower risk to human health,” and no health-based exposure limit is considered necessary.^[1] Under Option 1, a residue of 50 mg per day or less — corresponding to 5000 ppm, or 0.5 percent — is accepted without further justification, and higher amounts may be acceptable if supported.^[1][11] Ethanol, acetone, ethyl acetate, isopropanol, acetic acid and dimethyl sulfoxide are Class 3.

These figures belong to the regulated world of approved medicines; research-grade laboratory chemicals carry no equivalent legal requirement. They are set out here because they are the clearest published statement of how a residual-solvent number is judged, and because a research buyer reading a residual-solvent value is looking at the same units.

Permitted daily exposure and the two options

The Class 2 limits are not chosen arbitrarily; they are derived from a toxicological quantity called the permitted daily exposure, and the ppm figure is simply that quantity translated into a concentration. Understanding the translation explains why the limits take the values they do.

The permitted daily exposure (PDE) is defined as “the maximum acceptable intake per day of residual solvent in pharmaceutical products.”^[1] It is worked out from the most sensitive relevant toxicity study: the no-observed-effect level (or, failing that, the lowest-observed-effect level) is adjusted for body weight and then divided by a series of safety factors that account for extrapolating between species, for variation between individuals, for the length of the study, and for the severity of the effect.^[1] The result is a dose, in milligrams per day, that is considered acceptable with a wide margin. For the most hazardous Class 1 solvents, the same reasoning is applied with very large safety factors.^[1]

Turning a PDE into a concentration requires an assumption about how much product a person takes. ICH Q3C offers two ways to do it. Option 1 assumes a daily product intake of 10 g and applies a single formula, Concentration (ppm) = 1000 × PDE / dose, with the PDE in mg/day and the dose in g/day.^[1] For acetonitrile, whose PDE is 4.1 mg/day, this gives 1000 × 4.1 / 10 = 410 ppm — the number in the table above. “No further calculation is necessary provided the daily dose does not exceed 10 g.”^[1] Option 2 uses the same formula with the product’s actual maximum daily dose instead of the 10 g default, which gives a higher permitted concentration for a product taken in small amounts, provided the residue has still been “reduced to the practical minimum” and the total daily intake stays under the PDE.^[1]

The guideline adds that PDEs are given to the nearest 0.1 mg/day and concentrations to the nearest 10 ppm, and that when several residues are present in a drug product the amounts from each component are added so the total for each solvent stays under its PDE.^[1]

How the test works: static headspace GC

Residual solvents are measured by gas chromatography, and the sample is almost always introduced by static headspace sampling rather than by injecting the dissolved solid directly. The technique works because a volatile molecule in a sealed, warmed vial distributes itself between the liquid and the gas above it in a fixed, reproducible ratio — and that ratio can be pushed in favour of the gas.

Place a dissolved or suspended sample in a sealed vial and the volatile components “diffuse into the gas phase until the headspace has reached a state of equilibrium.”^[4] At equilibrium the distribution of each solvent is described by its partition coefficient, K = C_s / C_g, the ratio of its concentration in the sample phase to its concentration in the gas phase.^[4] A solvent with a low K is volatile and poorly held by the matrix, so it partitions readily into the gas and gives a strong signal; a solvent with a high K clings to the liquid and gives a weak one. The spread is enormous: in water at 40 °C, n-hexane has a K of about 0.14 while ethanol sits around 1355.^[4] A second quantity, the phase ratio β = V_g / V_s, is the volume of headspace relative to the volume of sample, and the concentration that actually reaches the column follows C_g = C₀ / (K + β), where C₀ is the original concentration in the sample.^[4]

Two levers raise the signal for the stubborn, high-K solvents. The first is temperature: warming the vial “will change the solubility of the analyte in the sample matrix and can be used to drive the equilibrium in favour of the gas phase,” and the effect is large — raising a vial from 40 °C to 80 °C lowers ethanol’s K from 1355 to about 328.^[4] This is why residual-solvent methods equilibrate at elevated temperatures, commonly around 80 to 85 °C for 40 to 60 minutes.^[4][5][6] The second is matrix modification: adding a salt such as sodium sulfate or sodium chloride to an aqueous sample — “salting out” — “decrease[s] the solubility of polar organic volatiles in the sample matrix and promote[s] their transfer into the headspace,” lowering K further.^[4]

The decisive advantage of sampling the headspace rather than the liquid is what stays behind. “Volatile components from complex sample mixtures can be extracted from non-volatile sample components and isolated in the headspace,” so the peptide or drug — high-boiling, sticky, non-volatile — remains in the vial and never reaches the inlet or the column.^[4] A direct injection of a dissolved peptide would foul the liner and the column head; headspace sampling sidesteps that entirely, which is why it is the preferred technique for residual solvents.^[9][11] Once the headspace aliquot is on the column, ordinary gas chromatography takes over: the solvents separate by their volatility and their affinity for the stationary phase, and a detector records each as a peak whose area is proportional to how much was present.

The method in the pharmacopoeia: USP <467>

The headspace principle is given a precise, named procedure in the pharmacopoeias, and a residual-solvent specification almost always points to one of them. In the United States the method is USP General Chapter <467>, Residual Solvents; in Europe it is European Pharmacopoeia chapter 2.4.24; both implement the ICH Q3C class structure and limits.^[3][11][13] USP <467> defines residual solvents in the same words as ICH Q3C and states that “it is only necessary to test for residual solvents that are used or produced in the manufacture or purification processes” — a laboratory does not screen for solvents the process never touched.^[3]

USP <467> is built around three headspace-GC procedures used in sequence.^[3][12] Procedure A is the screen and limit test: the sample is run on one column and each peak is compared against the corresponding Class 1 or Class 2 standard. If no peak reaches its limit, “the article meets the requirements of this test” and no further work is needed.^[3][13] Procedure B is a confirmation on a column of different polarity: any solvent that appeared to exceed its limit in Procedure A is re-examined, because two solvents that overlap on the first column generally separate on the second.^[3][6] Procedure C is the quantitative step, used only if Procedure B confirms an exceedance; it determines the actual concentration against a standard and a spiked sample.^[3]

The two columns are specified by their USP phase designations. Procedure A uses phase G43 — a “6% cyanopropylphenyl, 94% dimethylpolysiloxane” phase, the familiar 624-type column sold as DB-624, VF-624, SPB-624 or an equivalent — and Procedure B uses phase G16, a polyethylene-glycol (wax) phase.^[11][9][12] Detection is by flame ionization, which burns each solvent as it leaves the column and measures the ions produced, giving a quantitative signal across a wide dynamic range; the FID is the detector all three USP procedures use.^[10][12] Typical operating conditions put the headspace oven at about 80 to 85 °C for 40 to 60 minutes, inject a 1 mL loop of headspace gas, and run the G43 column from a low initial temperature up to around 240 °C.^[3][5][6] System suitability is checked before results are trusted: on the Procedure A column the resolution between acetonitrile and dichloromethane must be at least 1.0, and signal-to-noise minimums are set for the Class 1 marker peaks.^[3][12]

Sample preparation follows the solubility of the article. A water-soluble material is dissolved in water; a water-insoluble material is dissolved in an organic diluent — dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide or 1,3-dimethyl-2-imidazolidinone are the usual choices, each selected to dissolve the sample without contributing a peak of its own.^[3][9] The chapter also notes that a few solvents, among them formamide, 2-ethoxyethanol, N-methylpyrrolidone and sulfolane, are “not readily detected” under the standard headspace conditions and need a different validated procedure.^[3] And where only Class 3 solvents can be present, a non-specific method such as loss on drying may be used instead of GC.^[1][11]

Residual solvents in peptide manufacture

A synthetic peptide passes through more organic solvent, gram for gram, than most small molecules, which is why residual-solvent data is a meaningful quality signal for one. Each stage of solid-phase peptide synthesis and purification leaves a candidate residue, and the solvents are well known.

The reaction medium for Fmoc synthesis is N,N-dimethylformamide (DMF), often with N-methylpyrrolidone (NMP), and the resin is swelled and washed in dichloromethane.^[14][15][16] Each cycle removes the Fmoc protecting group with piperidine — typically a 20 percent solution of piperidine in DMF — which is then washed away.^[15][16] The finished chain is cut from the resin with trifluoroacetic acid (TFA) and scavengers, after which the crude peptide is precipitated by adding cold diethyl ether or tert-butyl methyl ether (MTBE).^[14][15] Final purification is by reversed-phase HPLC in a water–acetonitrile gradient, usually with a trace of TFA or formic acid as a modifier, and the purified fraction is freeze-dried.^[14][15] Any of these can linger in the dried powder, which is exactly what a residual-solvent test looks for.

Most of the heavy hitters are Class 2. “DMF, NMP, DCM, and acetonitrile are generally Class 2 solvents, while ethyl acetate, ethanol, DMSO, and MTBE are generally Class 3,” as one peptide-manufacturing reference summarises it.^[14] That places DMF, NMP, dichloromethane and acetonitrile — the four most abundant peptide-process solvents — squarely among the solvents with defined ppm limits, while the ethers and alcohols used to precipitate and clean fall into the more forgiving Class 3. Piperidine and TFA are not individually listed in the ICH Q3C tables and are controlled under general good-manufacturing-practice and quality requirements rather than by a tabulated PDE.

One point of confusion is worth heading off. The TFA that cleaves the peptide and modifies the HPLC gradient also ends up paired with the peptide’s basic residues as the trifluoroacetate counterion, and that is a separate measurement from residual solvent. The counterion is not volatile in the headspace sense and is quantified by ion chromatography, HPLC or fluorine NMR and reported as counterion content — the subject of TFA vs Acetate in Peptides — rather than as a residual solvent. Likewise, residual water is measured not by GC but by Karl Fischer titration, covered in What Is Karl Fischer Titration.

GC-FID and GC-MS: quantify and confirm

Once the solvents are separated on the column, the choice of detector decides what the method can tell you. The two in common use — the flame ionization detector and the mass spectrometer — answer different questions, and good laboratories use both.

The flame ionization detector (FID) is the workhorse, and the one the compendial USP <467> procedures specify.^[10][12] It responds to almost any organic compound, has a wide linear range, and gives a stable, reproducible peak area, which makes it excellent for quantitation. What it does not do is identify a peak: the FID reports only that something organic eluted at a given time, so identity rests on retention time alone, and two solvents that elute together cannot be told apart. That is the reason USP <467> builds in a second column for Procedure B — a co-elution on the G43 phase is resolved on the G16 phase.^[3][6]

The mass spectrometer (MS) addresses identity directly. It records each solvent’s mass spectrum, a fragmentation fingerprint, so a peak is identified by what it is rather than by when it arrives. “MS detection provides better selectivity than FID because it combines spectral and chromatographic identification,” and “unique mass spectra often eliminate resolution requirements” — co-eluting solvents such as 1,2-dichloroethane and carbon tetrachloride, hard to separate on a column, are distinguished at once by their spectra.^[10] The trade-off is that the FID keeps a wider dynamic range and simpler quantitation, so a common division of labour is GC-FID for routine measurement against the limits and GC-MS to confirm the identity of an unexpected peak or to resolve one the columns cannot.^[9][10] Isomers with near-identical spectra, such as the xylenes, remain a case where retention time is still the deciding evidence even with MS.^[10]

Residual solvents on a certificate of analysis

Where residual solvents appear on a certificate of analysis, they sit apart from the purity and identity lines, and reading the entry correctly means knowing that it answers a question neither of those tests can. Purity by HPLC and identity by mass spectrometry describe the peptide; a residual-solvent line describes the process solvents left around it.

A complete entry names the solvent, gives a value in ppm (or states “not detected” with the detection limit), names the method — typically headspace GC-FID to USP <467> or Ph. Eur. 2.4.24 — and shows the limit it is judged against. A result is only interpretable against that limit and that method, as the sections above explain, and a “not detected” means the solvent was below the method’s threshold, not that it is provably absent. It is also specific to the lot tested: residual-solvent content depends on how a particular batch was dried, so it cannot be inferred from a compound’s name or from this page. And it covers only what it measures — it says nothing about chemical purity, counterion content or net peptide content, the subjects of Peptide Impurities Explained and What Is Net Peptide Content.

For reference, Patriot Labs is a first-responder-owned, US-based company whose every batch is tested by an independent US laboratory, with the certificate of analysis published on the product page; the purity and identity figures on that certificate come from HPLC and mass spectrometry, the two measurements described in What Is HPLC and What Is Mass Spectrometry. Residual-solvent testing, where it is performed, is a separate assay from those two, run and reported by the headspace-GC methods set out here.

What this guide does not establish

This guide is an educational account of what residual solvents are and how they are measured. Several limits are worth stating plainly.

• It describes a test, not any specific product. Whether a given lot has been tested for residual solvents, and what values it returned, is a property of that lot and its certificate of analysis, not something that can be inferred from a compound’s name or from this page.
• The limits cited are regulatory. The ICH Q3C classes, PDEs and ppm limits apply to approved medicines under pharmacopoeial frameworks; research-grade laboratory chemicals carry no equivalent legal requirement, and the figures are given only as a reference point.^[1][3]
• Nothing here concerns use in a person or animal. The toxicity of individual solvents is described to explain why the test exists and why the limits are set; it is not a statement about any research compound, and this guide does not describe how to use any product.
• Nothing here describes where any peptide is made. The chemistry of residual solvents and the mechanics of the assay are general; they are not a claim about the origin, process or solvent content of any specific material.

Frequently asked questions

What is residual solvent testing?

Residual solvent testing measures the amount of volatile organic solvent left behind in a drug substance, excipient or synthetic peptide after it is manufactured and dried. The standard method is static headspace gas chromatography, which separates and quantifies each solvent, and the results are judged against the limits set in the ICH Q3C guideline and pharmacopoeial chapters such as USP General Chapter 467. It is a test for one specific class of impurity, leftover process solvents, not a measure of purity, identity or potency.

What is ICH Q3C?

ICH Q3C is the international guideline titled Impurities: Guideline for Residual Solvents, which defines which solvents may remain in a pharmaceutical and at what level. It sorts solvents into three classes by toxicity, assigns each a permitted daily exposure, and gives concentration limits in parts per million. The current version is Q3C(R9), adopted at ICH Step 4 in January 2024.

What are the three classes of residual solvents?

ICH Q3C groups residual solvents into three classes. Class 1 solvents are to be avoided: known or suspected human carcinogens and environmental hazards such as benzene, limited to 2 ppm, and carbon tetrachloride at 4 ppm. Class 2 solvents are to be limited because of lower-grade toxicity, each with a permitted daily exposure, for example acetonitrile at 410 ppm, dichloromethane at 600 ppm and methanol at 3000 ppm. Class 3 solvents have low toxic potential and are acceptable up to 50 mg per day, or 0.5 percent, without further justification.

How does headspace gas chromatography measure residual solvents?

In static headspace sampling the sample is dissolved in a diluent, sealed in a vial and heated so the volatile solvents evaporate into the gas space above the liquid, called the headspace, until they reach equilibrium. A fixed volume of that headspace gas is then injected onto a gas chromatography column, which separates the solvents so a detector can measure each one. The non-volatile peptide or drug stays in the vial, which is why the technique handles sticky, high-boiling materials cleanly.

Which residual solvents are found in synthetic peptides?

Synthetic peptides are built and purified in organic solvents, and traces of those solvents can remain in the final freeze-dried powder. The common ones are N,N-dimethylformamide (DMF) and N-methylpyrrolidone (NMP) used as the reaction medium, dichloromethane, the piperidine used to remove Fmoc protecting groups, the diethyl ether or tert-butyl methyl ether used to precipitate the crude peptide, and the acetonitrile used in reversed-phase HPLC purification. DMF, NMP, dichloromethane and acetonitrile are ICH Q3C Class 2 solvents, while ethanol, ethyl acetate and MTBE are Class 3.

Is residual solvent testing the same as measuring the TFA counterion?

No. Residual solvent testing by headspace gas chromatography measures volatile organic solvents that evaporate when heated. The trifluoroacetate (TFA) counterion that pairs with a peptide’s basic groups is not volatile in the same way and is measured separately, usually by ion chromatography, HPLC or fluorine NMR, and reported as counterion content rather than as a residual solvent.

What is the difference between GC-FID and GC-MS for residual solvents?

A flame ionization detector (FID) burns each solvent as it leaves the column and measures the ions produced, giving a reliable quantitative signal across a wide range, and it is the detector the USP 467 procedures use. A mass spectrometer (MS) instead records each solvent’s mass spectrum, which identifies a peak by its chemical fingerprint and can tell apart solvents that overlap on the column. Laboratories often use GC-FID for routine quantitation and GC-MS to confirm identity or resolve unexpected peaks.

References

1. International Council for Harmonisation. ICH Q3C(R9) Guideline on Impurities: Guideline for Residual Solvents. Adopted at Step 4, 24 January 2024; EMA/CHMP/ICH/82260/2006, effective 29 April 2024. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q3c-r9-guideline-impurities-guideline-residual-solvents-step-5_en.pdf
2. International Council for Harmonisation. Impurities: Guideline for Residual Solvents Q3C(R8), Step 4, 22 April 2021. https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf
3. United States Pharmacopeia. General Chapter <467> Residual Solvents, USP–NF. https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/generalChapter467Current.pdf
4. Restek Corporation. A Technical Guide for Static Headspace Analysis Using GC (partition coefficient, phase ratio, salting out). https://d1lqgfmy9cwjff.cloudfront.net/csi/pdf/e/rk67.pdf
5. Agilent Technologies (2016). Analysis of USP <467> Residual Solvents using Agilent J&W Columns and Headspace, publication 5991-7531EN. https://www.agilent.com/cs/library/applications/5991-7531EN.pdf
6. Agilent Technologies (2012). Analysis of USP <467> Residual Solvents with Improved Repeatability Using the Agilent 7697A Headspace Sampler, publication 5990-7625EN. https://www.agilent.com/cs/library/applications/5990-7625EN.pdf
7. Thermo Fisher Scientific (2010). Analysis of Residual Solvents Using GC/FID with Headspace (ISC 2010 poster). https://documents.thermofisher.com/TFS-Assets/CMD/posters/ISC_2010_-_Analysis_of_residual_solvents_using_GCFID_with_headspace.pdf
8. Thermo Fisher Scientific (2018). Simplified, cost-effective headspace GC method for residual solvents analysis in pharmaceutical products, Technical Note TN10681. https://documents.thermofisher.com/TFS-Assets/CMD/Technical-Notes/tn-10681-hs-gc-residual-solvents-pharmaceuticals-tn10681-en.pdf
9. Yazzie, D. T., Zhang, K., Chetwyn, N. P., et al. (2010). A Generic Headspace GC Method for Residual Solvents in Pharmaceuticals: Benefits, Rationale, and Adaptations for New Chemical Entities. LCGC North America, 28(1). https://www.chromatographyonline.com/view/generic-headspace-gc-method-residual-solvents-pharmaceutical-benefits-rationale-and-adaptations-new
10. Joyce, J., Wahab, S., & Belsky, I. Static Headspace GC–MS Detection of Residual Solvents: A Possible Simultaneous Identification and Quantitation Method. Chromatography Online (LCGC). https://www.chromatographyonline.com/view/static-headspace-gc-ms-detection-residual-solvents-possible-simultaneous-identification-and-quantita
11. MilliporeSigma (Sigma-Aldrich). Residual Solvents Testing by Gas Chromatography (ICH Q3C classes; USP <467> procedures, columns G43 and G16, FID). https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/analytical-chemistry/gas-chromatography/residual-solvents-testing-by-gas-chromatography
12. Phenomenex (2007). Understanding the Revisions to USP <467> Residual Solvents (whitepaper; Procedures A/B/C, G43 and G16 phases, system suitability). https://phx.phenomenex.com/lib/5107_ZEB_USP_467_Whitepaper.pdf
13. Shimadzu Corporation. Measurement of Residual Solvents in Pharmaceuticals by Headspace GC — USP Residual Solvents Procedure A. https://www.shimadzu.com/an/industries/small-molecule-pharmaceutical/development/residual-solvents/index.html
14. Pharmaffiliates (2026). What Chemical Solvents Are Used in Peptide Manufacturing: Selection & Stages. https://www.pharmaffiliates.com/en/blog/chemical-solvents-used-in-peptide-manufacturing
15. Wikipedia contributors. Peptide synthesis (Fmoc deprotection with piperidine in DMF, TFA cleavage with scavengers, reversed-phase HPLC purification, TFA salt). https://en.wikipedia.org/wiki/Peptide_synthesis
16. Wikipedia contributors. Fluorenylmethyloxycarbonyl protecting group (20% piperidine in DMF for Fmoc removal). https://en.wikipedia.org/wiki/Fluorenylmethyloxycarbonyl_protecting_group

For the other numbers on a research report, see Understanding Peptide COA Testing, Endotoxin Testing Explained and What Is Karl Fischer Titration; for the two analytical methods behind purity and identity, see What Is HPLC and What Is Mass Spectrometry.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes residual solvents and the methods used to detect them in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about the residual-solvent content, purity or manufacturing location of any specific product.